Amwill Health Care Limited concluded its 9th Annual General Meeting on August 14, 2026, with shareholders approving key governance resolutions and the company’s financial statements for FY26. The meeting was conducted through Video Conferencing or Other Audio-Visual Means in compliance with Ministry of Corporate Affairs and Securities and Exchange Board of India regulations. Twenty members were present to establish the requisite quorum.

Key Resolutions Approved

The primary business transacted at the meeting included the adoption of the audited financial statements for the fiscal year ended March 31, 2026, along with the reports of the Directors and Auditors. Shareholders also approved the declaration of a final dividend on equity shares for the same period. The Secretarial Audit Report for FY26 contained no qualifications, reservations, adverse remarks, or observations.

Board Appointments

Ms. Sapna Parmar was reappointed as a Non-Executive Director after retiring by rotation. In a special resolution, shareholders approved the reappointment of Mr. Tarun Gandhi and Mr. Anand Gandhi as Managing Directors. As Mr. Tarun Gandhi had an interest in these items, Independent Director Mr. Man Singh Gilundia chaired the proceedings for these specific resolutions before Mr. Gandhi resumed the chair.

Meeting Proceedings

Mr. Tarun Gandhi, Managing Director, presided over the meeting and provided an overview of the company’s financial performance and future outlook. Mr. Anand Gandhi, also a Managing Director, addressed members on operational performance and sales and marketing strategies. Ms. Anshu Anshuman, Company Secretary and Compliance Officer, coordinated the proceedings and confirmed the presence of statutory and secretarial auditors.

Independent Director Mr. Vasanth Kumar was unable to attend due to prior commitments but authorized Ms. Sapna Parmar to respond to queries related to the Nomination and Remuneration Committee. The remote e-voting facility, managed by National Depository Services Limited, remained open for 15 minutes after the conclusion of the meeting for shareholders who had not cast their votes remotely.

Amwill Health Care has adopted a hybrid treasury strategy to optimize surplus cash, with its Investment Committee approving aggregate investment limits of ₹33 crore across multiple asset classes on August 08, 2026. The move aims to capture higher post-tax, risk-adjusted returns on excess capital while anchoring primary liquid reserves in traditional Bank Fixed Deposits for operational liquidity. This structured approach allows the company to diversify beyond safe havens into measured active investments without compromising balance sheet safety.

The disclosure was made pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Master Circular no. (Ref: HO/49/14/14(7)2025-CFD-POD2/I/3762/2026) dated January 30, 2026. Anshu Anshuman, Company Secretary and Compliance Officer, signed the intimation submitted to the Bombay Stock Exchange. The company confirmed that these investments do not involve any related party transactions.

The Investment Committee defined specific ceilings for different segments of the portfolio. The largest allocation is reserved for debt-oriented instruments, followed by private credit and alternative funds. Equity exposure is capped at a lower threshold to manage volatility.

The debt segment, comprising Government Securities, Treasury Bills, Government Bonds, Non-Convertible Debentures, Commercial Papers, and other debt securities, carries an aggregate limit of ₹10,00,00,000. This portion serves as a stable component of the diversified portfolio, offering liquidity and safety comparable to bank deposits but with potentially better yield structures.

For higher-risk appetite allocations, the committee approved up to ₹15,00,00,000 for Private Credit Funds, Alternative Investment Funds, Structured Debt Instruments, and other debt-oriented opportunities. Additionally, ₹3,00,00,000 is allocated for invoice discounting platforms and long-term or short-term bonds. These instruments aim to generate superior risk-adjusted returns through active management and specialized credit strategies.

Equity exposure is strictly limited to ₹2,00,00,000 for investments in listed equity shares and subscriptions to Mainboard and SME Initial Public Offers. Mutual Fund investments, executed through Systematic Investment Plans in both Equity and Debt-Oriented Schemes, are capped at ₹3,00,00,000. This disciplined capping ensures that equity market fluctuations do not significantly impact the company’s core treasury position.

Strategic Implications

The shift from a purely conservative cash management stance to a hybrid model indicates Amwill Health Care’s confidence in its near-term liquidity requirements. By ring-fencing specific amounts for alternative investments and private credit, the company seeks to enhance overall return on idle cash. However, the strict adherence to aggregate limits and the exclusion of related-party transactions suggest a robust internal control mechanism designed to prevent overexposure to any single asset class or counterparty risk.